Characteristic | Data for patients who received | ||
Vancomycin | FDC | ||
Evaluable patients | 59 | 54 | |
Sex ratio―male:female [n (%)] | 37:22 (62.71%:37.29%) | 32:22 (59.25%:40.75%) | |
Age, mean year SD | 58.47 ± 14.67 | 59.85 ± 13.99 | |
APACHE II score | |||
<15 | 44 (74.57%) | 41 (75.92%) | |
≥15 | 15 (25.43%) | 13 (24.08%) | |
Co-morbidities | |||
Diabetes mellitus | 18 (30.50%) | 19 (35.18%) | |
Cardiac | 27 (45.76%) | 23 (42.59%) | |
Kidney | 7 (11.86%) | 4 (7.40%) | |
Chronic obstructive pulmonary disease (COPD) | 33 (55.93%) | 35 (64.81%) | |
Neurological disease | 9 (15.25%) | 10 (18.51%) | |
Pneumonia types | |||
Community associated | 8 (13.55%) | 7 (12.96%) | |
Health care-associated | 26 (44.06%) | 28 (51.85%) | |
Hospital associated | 22 (37.28%) | 15 (27.77%) | |
Ventilator associated | 31 (52.54%) | 28 (51.85%) | |